DOCSLIB.ORG

Prostate Cancer: Drugs and Their Side Effects Victor Mcpherson MD, Msc, FRCSC Assistant Professor Division of Urology, Department of Surgery Mcgill University

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prostate Cancer: Drugs and Their Side Effects Victor Mcpherson MD, Msc, FRCSC Assistant Professor Division of Urology, Department of Surgery Mcgill University 05/05/2021 Prostate Cancer: Drugs and their side effects Victor McPherson MD, MSc, FRCSC Assistant Professor Division of Urology, Department of Surgery McGill University COI Declaration TYPE OF AFFILIATION NAME OF ORGANIZATION DETAILS / DATE (from/to) TerSera May 26 2020 I am a member of an advisory board or similar committee for a Abbvie Oct 15 2020, Feb 25 2021 for-profit or non-profit organization I have received payment from a for-profit or non-profit TerSera Travel funding to GU ASCO Conference organization (including gifts, etc...) 2020 I am currently participating in or have participated in a clinical Bristol-Myers Squibb BCG and immunotherapy in non muscle trial within the past two years invasive bladder cancer 1 05/05/2021 Learning Objectives – Anti Androgen Drugs and their side effects -Overview of Prostate Cancer drugs: Focus on Anti-androgens -Non Steroidal Anti-Androgens -Bicalutimide -Androgen Deprivation Therapy -GnRH Antagonists -LHRH Agonists -Androgen Receptor Antagonists -Enzalutimide -Apalutimide -CYP17 Inhibitor -Abiraterone Prostate Cancer Therapeutic Landscape Adapted from: https://www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-prostate-cancer/119166-asco-gu-2020-treatment- selection-in-cspc-considerations-now-and-downstream-in-an-evolving-therapeutic-landscape-discussion-of-abstracts-82-and-162.html 2 05/05/2021 Non Steroidal Anti-Androgens - Competitive antagonists of androgen receptor - NB: *Partial Agonists - Bicalutimide/Casodex most commonly used - ->50mg PO Daily - ->Used to suppress testosterone flare from LHRH agonists - ->Used in total androgen blockade (limited use currently) Cancer Care Ontario: https://www.cancercareontario.ca/en/drugformulary/drugs/bicalutamide Non Steroidal Anti-Androgens - Side effects: - Diarrhea (10%) -Fatigue - Gynecomastia and breast tenderness: more common in monotherapy (38%) - Hot flashes: monotherapy (12%) - Erectile function not significantly altered with bicalutamide monotherapy Cancer Care Ontario: https://www.cancercareontario.ca/en/drugformulary/drugs/bicalutamide BC Cancer Agency: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Bicalutamide_monograph_1October2011.pdf 3 05/05/2021 Non Steroidal Anti-Androgens Cancer Care Ontario: https://www.cancercareontario.ca/en/drugformulary/drugs/bicalutamide GnRH Antagonists and LHRH Agonist https://www.urotoday.com/journal/everyday-urology-oncology-insights/articles/96381-assessment-of-cardiovascular-risk-with-the-use-of- androgen-deprivation-therapy-for-prostate-cancer-everyday-urology-full-text-article.html 4 05/05/2021 LHRH Agonists - LHRH Agonist mechanism of action: - Overactivation of hypothalamus-pituitary axis leads to suppression - Temporary spike in Testosterone seen: NB in patients with high volume PCa - Can block with NSAA - Eligard (Leuprolide Acetate); 1/3/4/6 month depo injections - Zoladex (Goserelin Acetate); 1/3 - Lupron (Leuprolide Acetate); 1/3/4/6 - Trelstar (Triptorelin); 1/3/6 GnRH Antagonists - Direct GnRH Antagonist - Degarelix/Firmagon - 240mg SC loading dose - 80mg SC q monthly - Injection site reactions common - Possibly lower risk of cardiovascular toxicity – ongoing area of research BC Cancer: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Degarelix_monograph_1Feb2015.pdf 5 05/05/2021 https://www.cua.org/system/files/Guidelines/7355_Guideline_ADT_Epub.pdf https://www.cua.org/system/files/Guidelines/7355_Guideline_ADT_Epub.pdf 6 05/05/2021 ADT Side Effects • Retrospective data: • Cardiac Events HR 1.38 in retrospective study • Cardiovascular mortality HR 1.17 • Highest risk among men with pre-exisiting CVD Controversy regarding LHRH gonists vs GnRH Antagonists https://www.cua.org/system/files/Guidelines/7355_Guideline_ADT_Epub.pdf ADT Side Effects • Hot Flash Medications – NB None Health Canada Approved for this indication • Venlafaxine (Effexor) 75 mg orally daily • Medroxyprogesterone acetate (Provera) 20 mg orally daily • Cyproterone acetate (Androcur) 100 mg orally daily • Gabapentin (Neurontin) 900 mg orally daily • Megestrol acetate (Megace) 20 mg orally twice daily https://www.cua.org/system/files/Guidelines/7355_Guideline_ADT_Epub.pdf 7 05/05/2021 ADT Side Effects https://www.cua.org/system/files/Guidelines/7355_Guideline_ADT_Epub.pdf Androgen Receptor Antagonists Rajaram P, Rivera A, Muthima K, Olveda N, Muchalski H, Chen QH. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. Molecules. 2020 May 24;25(10):2448. doi: 10.3390/molecules25102448. PMID: 32456317; PMCID: PMC7287767. 8 05/05/2021 Enzalutimide -Enzalutimide -First 2nd generation androgen receptor antagonists - 80-160mg PO Daily BC Cancer: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Degarelix_monograph_1Feb2015.pdf Enzalutimide -Enzalutimide - Most common: Fatigue, MSK pain, ↑lfts, diarrhea, androgen deprivation symptoms, edema, headache, HTN, dizziness, insomnia - Increased seizure risk http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Enzalutamide_monograph_1Oct2015.pdf 9 05/05/2021 Enzalutimide http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Enzalutamide_monograph_1Oct2015.pdf Enzalutimide https://www.cancercareontario.ca/sites/ccocancercare/files/enzalutamide.pdf 10 05/05/2021 Apalutimide - Apalutimide/Erleada -2nd generation androgen receptor antagonist - 120-240mg PO Daily http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Apalutamide_monograph.pdf Apalutimide http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Apalutamide_monograph.pdf 11 05/05/2021 Apalutimide - Rash: up to 25%; some grade 3-4 - median onset within 3 months - usually resolves within 2 months - recurs in up to 50% with rechallenge - treatment: corticosteroids and antihistamines +/- dose reduction/interruption/discontinuation - Siezure: increased risk with apalutimide as well http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Apalutamide_monograph.pdf Apalutimide http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Apalutamide_monograph.pdf 12 05/05/2021 Apalutimide https://www.cancercareontario.ca/en/drugformulary/drugs/apalutamide Abiraterone Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer Neeraj Agarwal, Thomas E Hutson, Nicholas J Vogelzang, and Guru Sonpavde Future Oncology 2010 6:5, 665-679 13 05/05/2021 Abiraterone - Abiraterone/Zytiga - CYP17 Inhibitor - 1000mg PO Daily + 5,g PO daily prednisone http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Abiraterone_monograph.pdf Abiraterone http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Abiraterone_monograph.pdf 14 05/05/2021 Abiraterone -Fatigue - Mineralocorticoid effects: ACTH increase - hypertension/hypokalemia/fluid retention - concomitant use of prednisone prevents - Hepatotoxicity; usually w/in 3 months http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Abiraterone_monograph.pdf Abiraterone http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Abiraterone_monograph.pdf 15 05/05/2021 Abiraterone https://www.cancercareontario.ca/en/drugformulary/drugs/abiraterone References 1. https://www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-prostate-cancer/119166-asco-gu-2020-treatment- selection-in-cspc-considerations-now-and-downstream-in-an-evolving-therapeutic-landscape-discussion-of-abstracts-82-and- 162.html 2. Cancer Care Ontario: https://www.cancercareontario.ca/en/drugformulary/drugs/bicalutamide 3. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Bicalutamide_monograph_1October2011.pdf 4. https://www.urotoday.com/journal/everyday-urology-oncology-insights/articles/96381-assessment-of-cardiovascular-risk-with- the-use-of-androgen-deprivation-therapy-for-prostate-cancer-everyday-urology-full-text-article.html 5. BC Cancer: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Degarelix_monograph_1Feb2015.pdf 6. https://www.cua.org/system/files/Guidelines/7355_Guideline_ADT_Epub.pdf 7. Rajaram P, Rivera A, Muthima K, Olveda N, Muchalski H, Chen QH. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. Molecules. 2020 May 24;25(10):2448. doi: 10.3390/molecules25102448. PMID: 32456317; PMCID: PMC7287767. 8. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Enzalutamide_monograph_1Oct2015.pdf 9. https://www.cancercareontario.ca/sites/ccocancercare/files/enzalutamide.pdf 9. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Apalutamide_monograph.pdf 10. https://www.cancercareontario.ca/en/drugformulary/drugs/apalutamide 11. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer Neeraj Agarwal, Thomas E Hutson, Nicholas J Vogelzang, and Guru Sonpavde Future Oncology 2010 6:5, 665-679 12. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Abiraterone_monograph.pdf 13. https://www.cancercareontario.ca/en/drugformulary/drugs/abiraterone 16 05/05/2021 17.
Load more

Recommended publications
  • Risk of Breast Cancer After Stopping Menopausal Hormone Therapy In
    Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort Agnès Fournier, Sylvie Mesrine, Laure Dossus, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Nathalie Chabbert-Buffet To cite this version: Agnès Fournier, Sylvie Mesrine, Laure Dossus, Marie-Christine Boutron-Ruault, Françoise Clavel- Chapelon, et al.. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment, Springer Verlag, 2014, 145 (2), pp.535-43. 10.1007/s10549- 014-2934-6. inserm-01319982 HAL Id: inserm-01319982 https://www.hal.inserm.fr/inserm-01319982 Submitted on 23 May 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. TITLE PAGE Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort Authors : Agnès Fournier1,2,3, Sylvie Mesrine1,2,3, Laure Dossus1,2,3, Marie-Christine Boutron- Ruault1,2,3, Françoise Clavel-Chapelon1,2,3, Nathalie Chabbert-Buffet4 Affiliations: 1. Inserm, Center for research in Epidemiology and Population Health, U1018, Nutrition, Hormones and Women’s Health team, F-94807, Villejuif, France 2. Univ Paris-Sud, UMRS 1018, F-94807, Villejuif, France 3. Institut Gustave Roussy, F-94805, Villejuif, France 4.
    [Show full text]
  • Classification and Pharmacology of Progestins
    Maturitas 46S1 (2003) S7–S16 Classification and pharmacology of progestins Adolf E. Schindler a,∗, Carlo Campagnoli b, René Druckmann c, Johannes Huber d, Jorge R. Pasqualini e, Karl W. Schweppe f, Jos H. H. Thijssen g a Institut für Medizinische Forschung und Fortbildung, Universitätsklinikum, Hufelandstr. 55, Essen 45147, Germany b Ospedale Ginecologico St. Anna, Corso Spezia 60, 10126 Torino, Italy c Ameno-Menopause-Center, 12, Rue de France, 06000 Nice, France d Abt. für Gynäkologische Endokrinologie, AKH Wien, Währingergürtel 18-20, 1090 Wien, Austria e Institute de Puériculture26, Boulevard Brune, 75014 Paris, France f Abt. für Gynäkologie und Geburtshilfe, Ammerland Klinik, Langestr.38, 26622 Westerstede, Germany g Department of Endocrinology, Universitair Medisch Centrum Utrecht, P.O. Box 85090, 3508 AB Utrecht, The Netherlands Abstract Besides the natural progestin, progesterone, there are different classes of progestins, such as retroprogesterone (i.e. dydroges- terone), progesterone derivatives (i.e. medrogestone) 17␣-hydroxyprogesterone derivatives (i.e. chlormadinone acetate, cypro- terone acetate, medroxyprogesterone acetate, megestrol acetate), 19-norprogesterone derivatives (i.e. nomegestrol, promege- stone, trimegestone, nesterone), 19-nortestosterone derivatives norethisterone (NET), lynestrenol, levonorgestrel, desogestrel, gestodene, norgestimate, dienogest) and spironolactone derivatives (i.e. drospirenone). Some of the synthetic progestins are prodrugs, which need to be metabolized to become active compounds. Besides
    [Show full text]
  • Role of Androgens, Progestins and Tibolone in the Treatment of Menopausal Symptoms: a Review of the Clinical Evidence
    REVIEW Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence Maria Garefalakis Abstract: Estrogen-containing hormone therapy (HT) is the most widely prescribed and well- Martha Hickey established treatment for menopausal symptoms. High quality evidence confi rms that estrogen effectively treats hot fl ushes, night sweats and vaginal dryness. Progestins are combined with School of Women’s and Infants’ Health The University of Western Australia, estrogen to prevent endometrial hyperplasia and are sometimes used alone for hot fl ushes, King Edward Memorial Hospital, but are less effective than estrogen for this purpose. Data are confl icting regarding the role of Subiaco, Western Australia, Australia androgens for improving libido and well-being. The synthetic steroid tibolone is widely used in Europe and Australasia and effectively treats hot fl ushes and vaginal dryness. Tibolone may improve libido more effectively than estrogen containing HT in some women. We summarize the data from studies addressing the effi cacy, benefi ts, and risks of androgens, progestins and tibolone in the treatment of menopausal symptoms. Keywords: androgens, testosterone, progestins, tibolone, menopause, therapeutic Introduction Therapeutic estrogens include conjugated equine estrogens, synthetically derived piperazine estrone sulphate, estriol, dienoestrol, micronized estradiol and estradiol valerate. Estradiol may also be given transdermally as a patch or gel, as a slow release percutaneous implant, and more recently as an intranasal spray. Intravaginal estrogens include topical estradiol in the form of a ring or pessary, estriol in pessary or cream form, dienoestrol and conjugated estrogens in the form of creams. In some countries there is increasing prescribing of a combination of estradiol, estrone, and estriol as buccal lozenges or ‘troches’, which are formulated by private compounding pharmacists.
    [Show full text]
  • Solubility of Bicalutamide, Megestrol Acetate, Prednisolone
    Article pubs.acs.org/jced Solubility of Bicalutamide, Megestrol Acetate, Prednisolone, Beclomethasone Dipropionate, and Clarithromycin in Subcritical Water at Different Temperatures from 383.15 to 443.15 K † ⊥ ‡ † ⊥ † † † Yuan Pu, , Fuhong Cai, Dan Wang,*, , Yinhua Li, Xiaoyuan Chen, Amadou G. Maimouna, † † † ⊥ † § Zhengxiang Wu, Xiaofei Wen, Jian-Feng Chen, , and Neil R. Foster , † Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Organic−Inorganic Composites, Beijing University of Chemical Technology, Beijing 100029, China ‡ College of Mechanical and Electrical Engineering, Hainan University, Haikou 570228, China § Department of Chemical Engineering, Curtin University, Perth, Western Australia 6102, Australia ⊥ Research Center of the Ministry of Education for High Gravity Engineering and Technology, Beijing University of Chemical Technology, Beijing 100029, China ABSTRACT: The solubility of bicalutamide, megestrol acetate, prednisolone, beclomethasone dipropionate, and clarithromycin in subcritical water (SBCW) at the temperature range from 383.15 to 443.15 K and constant pressure of 5.5 MPa were measured using a modified solvent−antisolvent method combined with SBCW technology. The chemical structures of these five kinds of solutes were stable after processed in SBCW at up to 443.15 K, which was demonstrated by Fourier transformed infrared analysis. The solubility of selected solutes increased exponentially as the temperature of the SBCW increased from 383.15 to 443.15 K. The obtained
    [Show full text]
  • The Role of Highly Selective Androgen Receptor (AR) Targeted
    P h a s e I I S t u d y o f I t r a c o n a z o l e i n B i o c h e m i c a l R e l a p s e Version 4.0: October 8, 2014 CC# 125513 CC# 125513: Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse Investigational Agent: Itraconazole IND: IND Exempt (IND 116597) Protocol Version: 4.0 Version Date: October 8, 2014 Principal Investigator: Rahul Aggarwal, M.D., HS Assistant Clinical Professor Division of Hematology/Oncology, Department of Medicine University of California San Francisco 1600 Divisadero St. San Francisco, CA94115 [email protected] UCSF Co-Investigators: Charles J. Ryan, M.D., Eric Small, M.D., Professor of Medicine Professor of Medicine and Urology Lawrence Fong, M.D., Terence Friedlander, M.D., Professor in Residence Assistant Clinical Professor Amy Lin, M.D., Associate Clinical Professor Won Kim, M.D., Assistant Clinical Professor Statistician: Li Zhang, Ph.D, Biostatistics Core RevisionHistory October 8, 2014 Version 4.0 November 18, 2013 Version 3.0 January 28, 2013 Version 2.0 July 16, 2012 Version 1.0 Phase II - Itraconazole Page 1 of 79 P h a s e I I S t u d y o f I t r a c o n a z o l e i n B i o c h e m i c a l R e l a p s e Version 4.0: October 8, 2014 CC# 125513 Protocol Signature Page Protocol No.: 122513 Version # and Date: 4.0 - October 8, 2014 1.
    [Show full text]
  • Hormonal and Non-Hormonal Management of Vasomotor Symptoms: a Narrated Review
    Central Journal of Endocrinology, Diabetes & Obesity Review Article Corresponding authors Orkun Tan, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology Hormonal and Non-Hormonal and Infertility, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 75390 and ReproMed Fertility Center, 3800 San Management of Vasomotor Jacinto Dallas, TX 75204, USA, Tel: 214-648-4747; Fax: 214-648-8066; E-mail: [email protected] Submitted: 07 September 2013 Symptoms: A Narrated Review Accepted: 05 October 2013 Orkun Tan1,2*, Anil Pinto2 and Bruce R. Carr1 Published: 07 October 2013 1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology Copyright and Infertility, University of Texas Southwestern Medical Center, USA © 2013 Tan et al. 2Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, ReproMed Fertility Center, USA OPEN ACCESS Abstract Background: Vasomotor symptoms (VMS; hot flashes, hot flushes) are the most common complaints of peri- and postmenopausal women. Therapies include various estrogens and estrogen-progestogen combinations. However, both physicians and patients became concerned about hormone-related therapies following publication of data by the Women’s Health Initiative (WHI) study and have turned to non-hormonal approaches of varying effectiveness and risks. Objective: Comparison of the efficacy of non-hormonal VMS therapies with estrogen replacement therapy (ERT) or ERT combined with progestogen (Menopausal Hormone Treatment; MHT) and the development of literature-based guidelines for the use of hormonal and non-hormonal VMS therapies. Methods: Pubmed, Cochrane Controlled Clinical Trials Register Database and Scopus were searched for relevant clinical trials that provided data on the treatment of VMS up to June 2013.
    [Show full text]
  • Megestrol Acetate
    Market Applicability Market GA KY MD NJ NY WA Applicable X X X X X X Megestrol acetate Override(s) Approval Duration Prior Authorization 1 year Medications megestrol acetate suspension (Megace Suspension and Megace ES Suspension) megestrol acetate tablets (Megace tablets) APPROVAL CRITERIA Requests for megestrol acetate suspension (Megace Suspension and Megace ES Suspension) may be approved if the following criteria are met: I. Individual has a diagnosis of one of the following: A. Cachexia, or an unexplained significant weight loss in individuals with HIV/AIDS; OR B. Ovarian cancer, including epithelial , fallopian tube, and primary peritoneal cancers (NCCN 2A); OR C. Cachexia and/or anorexia in individuals with cancer/neoplastic disease (DrugPoints B IIa, AHFS). Requests for megestrol acetate tablets (Megace tablets) may be approved if the following criteria are met: I. Individual has a diagnosis of one of the following: A. Advanced, inoperable, recurrent Breast cancer; AND B. Individual is using for palliative management; OR C. Endometrial/uterine cancer; AND D. Individual is using for palliative management; OR E. Persistent or recurrent Ovarian cancer, including epithelial , fallopian tube, and primary peritoneal cancers (NCCN 2A); PAGE 1 of 2 09/08/2020 CRX-ALL-0596-20 New Program Date 10/01/2018 This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply. Market Applicability Market GA KY MD NJ NY WA Applicable X X X X X X OR F. Cachexia and/or anorexia in individuals with cancer/neoplastic disease (DrugPoints B IIa, AHFS).
    [Show full text]
  • Ultra-Low-Dose Oral Contraceptive Pill: a New Approach to a Conventional Requirement
    International Journal of Reproduction, Contraception, Obstetrics and Gynecology Ahuja M et al. Int J Reprod Contracept Obstet Gynecol. 2017 Feb;6(2):364-370 www.ijrcog.org pISSN 2320-1770 | eISSN 2320-1789 DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20170006 Review Article Ultra-low-dose oral contraceptive pill: a new approach to a conventional requirement Meenakshi Ahuja1, Pramod Pujari2* 1Senior Consultant Obstetrician and Gynecologist, Max Super Specialty Hospital, Saket, New Delhi, India 2Medical Advisor, Pfizer limited, Mumbai, Maharashtra, India Received: 05 December 2016 Accepted: 17 December 2016 *Correspondence: Dr. Pramod Pujari, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Combined oral contraceptives (COCs) offer a convenient, safe, effective, and reversible method of contraception. However, their use is limited by side effects. Several strategies have been suggested to make COC use more acceptable among women. Reduction in the dose of estrogen is a commonly accepted approach to reduce the side effects of COC. Use of newer generation of progestins, such as gestodene, reduces the androgenic side effects generally associated with progestogens. Furthermore, reduction in hormone-free interval, as a 24/4 regimen, can reduce the risk of escape ovulation (hence preventing contraceptive failure) and breakthrough bleeding. It also reduces hormonal fluctuations, thereby reducing the withdrawal symptoms. A COC with gestodene 60 µg and ethinylestradiol (EE) 15 µg offers the lowest hormonal dose in 24/4 treatment regimen.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    ECOG-ACRIN Operations Office – Boston Frontier Science 900 Commonwealth Avenue Boston, MA 02215 (617) 632-3610 Fax: (617) 632-2990 Randomization: (617) 632-2022 Group Chair: Robert L. Comis, M.D. and Mitchell Schnall, M.D. Jean MacDonald, Director of Research Operations Group Statistician: Robert Gray, Ph.D. and Constantine Gatsonis, Ph.D. Mary Steele, Director of Group Administration July 31, 2014 Martha Kruhm, MS RAC Head, Protocol and Information Office Quality Assurance Section CTEP, DCT, NCI 6130 Executive Blvd, EPN Room 7000 Bethesda, MD 20892 Dear Ms. Kruhm: Enclosed is Addendum #9 to E2809, Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy. The following revisions to E2809 protocol have been made in this addendum: Section Change 1. Cover Page Updated the version date. Inserted into the first and second bullet points the phrase "confirmed on 2. Section 6.1.4 two consecutive additional determinations taken at least 4 weeks apart," to more clearly define undetectable PSA. The following revisions to E2809 Informed Consent Document have been made in this addendum: Section Change 1. Cover Page Updated the version date. "What side effects or Updated the risk section language to correspond with the condensed 2. risks can I expect from risk lists format. being in the study?" "What side effects or 3. risks can I expect from Inserted condensed risk list for Bicalutamide. being in the study?" If you have any questions regarding this addendum, please contact [email protected] or 617-632-3610.
    [Show full text]
  • How Are Interactions Taken Into Account in Studies on Conventional
    Original Article 933 How are Interactions Taken into Account in Studies on Conventional and Complementary Therapies for Breast Cancer Patients with Menopausal Complaints? Wie werden Interaktionen in Studien zur konventionellen und komplementären Therapie bei menopausalen Beschwerden von Brustkrebspatientinnen berücksichtigt? Authors J. Hübner1, K. Münstedt 2, R. Mücke3, O. Micke4 Affiliations 1 Dr. Senckenbergisches Chronomedizinisches Institut, Universität Frankfurt, Frankfurt 2 Frauenklinik, Universitätsklinikum Gießen, Gießen 3 Strahlentherapie, Klinikum Lippe, Lippe 4 Strahlentherapie, Franziskus Hospital, Bielefeld Key words Abstract Zusammenfassung l" breast cancer ! ! l" antihormone therapy Introduction: Postmenopausal symptoms in Einleitung: Postmenopausale Symptome bei l" hormone withdrawal signs breast cancer patients undergoing antihormone Mammakarzinompatientinnen unter antihormo- l" complementary medicine treatment lead to high drop-out rates from the neller Therapie führen zu einer hohen Abbrecher- l" interactions therapy. From the therapeutic point of view, rate der Therapie. Therapeutisch kommen Metho- Schlüsselwörter methods of both conventional and complemen- den der konventionellen wie der komplementä- l" Mammakarzinom tary medicine are concerned. Interactions are ren Medizin infrage. Bei den natürlichen Substan- l" antihormonelle Therapie being discussed in cases of natural substances. zen werden Interaktionen diskutiert. Sie betreffen l" Hormonentzugs- However, they are also relevant for conventional aber auch Substanzen
    [Show full text]
  • Gynaecomastia in a Tom-Cat Caused by Cyproterone Acetate: a Case Report
    Veterinarni Medicina, 52, 2007 (11): 521–525 Case Report Gynaecomastia in a tom-cat caused by cyproterone acetate: a case report F. Jelinek1, R. Barton2, J. Posekana2, L. Hasonova3 1Veterinary Histopathological Laboratory, Prague, Czech Republic 2Veterinary Clinic of Small Animals, Ceske Budejovice, Czech Republic 3Faculty of Agriculture, University of South Bohemia, Ceske Budejovice, Czech Republic ABSTRACT: The contribution demonstrates gynaecomastia in an adult, noncastrated tom-cat, caused by an antiandrogenic preparation Androcur tablets (Schering AG, BRD), administrated at the dose of 5 mg/day for one week. Two months after the treatment, the enlargement of all mammary glands was apparent and one month later (i.e. three months after the end of drug administration) the mammary chains reached the size of 30 × 15 × 20 cm. The general health state of the animal was altered due to the conspicuous enlargement and inflammation of mammary glands. Radical mastectomy was done under general anaesthesia using Isoflurane Rhone-Poulenc inh. The weight of the extirpated mammary chains was 1.75 kg. The healing of operative wounds and convalescence occurred without complications. Fibroepithelial hyperplasia of mammary glands was diagnosed histologically. Keywords: tom-cat; gynaecomastia; Androcur The sexual activity of intact male cats manifests is an antiandrogenic drug used in human medicine. itself by a urine spraying of the territory that is The effective substance of the tablets is cyproter- unpleasant, especially when the cat is kept indoors one acetate, which is a steroid antiandrogen that (Dolezel et al., 2001). This behaviour can be elimi- specifically blocks the effects of androgens at the nated substantially by means of surgical castration.
    [Show full text]
  • Effects of Tibolone on Climacteric Symptoms and Quality of Life in Breast Cancer
    Maturitas 70 (2011) 365–372 Contents lists available at SciVerse ScienceDirect Maturitas j ournal homepage: www.elsevier.com/locate/maturitas Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients—Data from LIBERATE trial a,∗ b c a d d Piero Sismondi , Rainer Kimmig , Ernst Kubista , Nicoletta Biglia , Jan Egberts , Roel Mulder , d a d e Juan Planellas , Giulia Moggio , Mirjam Mol-Arts , Peter Kenemans a Academic Department of Obstetrics and Gynaecology, University of Torino Medical School, Mauriziano Umberto I Hospital, 10100 Turin, Italy b University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany c Department of Obstetrics, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria d MSD, Oss, The Netherlands e Department of Obstetrics and Gynaecology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands a r t i c l e i n f o a b s t r a c t Article history: Background: Climacteric symptoms such as hot flushes and vaginal dryness are very common in breast Received 22 June 2011 cancer patients, resulting either from age or adjuvant therapy. Tibolone, a synthetic steroid, is effective Received in revised form 5 September 2011 in reducing these symptoms in healthy post-menopausal women, but this has never been studied in a Accepted 7 September 2011 large breast cancer population. Objectives: The primary objective of LIBERATE trial was to study safety of tibolone 2.5 mg daily versus placebo as primary, in symptomatic breast cancer survivors. The aim of this present paper was to report Keywords: effects of tibolone on climacteric symptoms, vaginal dryness and health-related quality of life in the study Tibolone Liberate population.
    [Show full text]